Biocept, Inc.
BIOC
BIOC was delisted on the 24th of October, 2023.
13 hedge funds and large institutions have $285K invested in Biocept, Inc. in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
63% more funds holding
Funds holding: 8 → 13 (+5)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
56% less capital invested
Capital invested by funds: $654K → $285K (-$368K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$119K |
| 2 |
Renaissance Technologies
New York
|
+$73.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$46.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$30.1K |
| 5 |
Jane Street
New York
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$142K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Dimensional Fund Advisors
Austin,
Texas
| $95K | +$119K | +237 | +181% |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $49K | -$142K | -283 | -60% |
|
|
3
Renaissance Technologies
New York
| $38K | +$73.8K | +147 | New |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $30K | +$46.2K | +92 | +368% |
|
5
BlackRock
New York
| $23K | – | – | – |
|
|
TSS
6
Two Sigma Securities
New York
| $16K | +$30.1K | +60 | New |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $12K | -$10K | -20 | -30% |
|
|
8
Jane Street
New York
| $11K | +$22.1K | +44 | New |
|
9
Macquarie Group
Sydney, NSW 2000,
Australia
| $7K | +$14.1K | +28 | New |
|
10
Morgan Stanley
New York
| $3K | +$6.53K | +13 | New |
|
11
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
FDCDDQ
12
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $486 | – | – | – |
|
BIOC Hedge Fund Activity: Q4 2018 in Review
13 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q4 2018, worth a combined $285K — down 56% from $654K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BIOC positions and 0 closed out — a net gain of 5 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $119K. The largest seller was Sabby Management, cutting an estimated $142K.
- 13 institutional investors held Biocept, Inc. (BIOC) as of Q4 2018, up from 8 in Q3 2018.
- Funds reported $285K of Biocept, Inc. stock for Q4 2018, down 56% quarter-over-quarter.
- 5 funds opened new Biocept, Inc. positions in Q4 2018 and 0 closed out, a net change of +5 holders.
- The largest Biocept, Inc. buyer in Q4 2018 was Dimensional Fund Advisors, an estimated $119K added.
- The largest Biocept, Inc. seller in Q4 2018 was Sabby Management, an estimated $142K sold.
Based on aggregated 13F filings for Q4 2018.